Completed PHASE3 INTERVENTIONAL NCT00033839

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache

Sponsor: Winston Laboratories

Conditions Episodic Cluster Headache

Interventions Civamide (Zucapsaicin)

Updated 6 times since 2017 Last updated: Jun 8, 2011 Started: Jan 31, 2002 Primary completion: Jul 31, 2003 Completion: Jul 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00033839, this PHASE3 trial focuses on Episodic Cluster Headache and remains completed. Sponsored by Winston Laboratories, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Winston Laboratories

Data source: Winston Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Ann Arbor, United States , Chesterfield, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Decatur, United States , Detroit, United States , Greensboro, United States , Houston, United States and 16 more locations